Advanced Cell Technology, Inc. & USA Graphite Inc. Trend Analysis Report: (OTCQB: ACTC), (OTCQB: USGT)
Advanced Cell Technology, Inc. (OTCQB:ACTC). The stock has extended its gains after the company announced that it achieved clinical milestone. The company said that investigators for its Phase 1/2 clinical trials for Stargardt’s macular dystrophy (SMD) and dry age-related macular degeneration (dry AMD) observed evidence of engraftment of the transplanted hESC-derived retinal pigment cells and visual acuity in patients treated over 18 months.
View full press release